Gilead Sciences, Inc. (GILD) Shares Bought by Swiss National Bank

Swiss National Bank boosted its stake in shares of Gilead Sciences, Inc. (NASDAQ:GILD) by 0.9% in the 3rd quarter, according to its most recent disclosure with the SEC. The institutional investor owned 4,817,324 shares of the biopharmaceutical company’s stock after acquiring an additional 41,800 shares during the period. Swiss National Bank owned 3,685.79% of Gilead Sciences worth $390,300,000 at the end of the most recent quarter.

A number of other institutional investors and hedge funds also recently bought and sold shares of the stock. Keel Point LLC grew its stake in Gilead Sciences by 0.4% during the second quarter. Keel Point LLC now owns 3,123 shares of the biopharmaceutical company’s stock valued at $221,000 after acquiring an additional 12 shares in the last quarter. Paradigm Financial Advisors LLC grew its stake in shares of Gilead Sciences by 0.3% in the 2nd quarter. Paradigm Financial Advisors LLC now owns 8,723 shares of the biopharmaceutical company’s stock worth $617,000 after buying an additional 26 shares in the last quarter. West Oak Capital LLC grew its stake in shares of Gilead Sciences by 0.7% in the 2nd quarter. West Oak Capital LLC now owns 4,666 shares of the biopharmaceutical company’s stock worth $330,000 after buying an additional 32 shares in the last quarter. First Heartland Consultants Inc. grew its stake in shares of Gilead Sciences by 0.4% in the 2nd quarter. First Heartland Consultants Inc. now owns 8,927 shares of the biopharmaceutical company’s stock worth $632,000 after buying an additional 39 shares in the last quarter. Finally, Princeton Portfolio Strategies Group LLC grew its stake in shares of Gilead Sciences by 0.4% in the 2nd quarter. Princeton Portfolio Strategies Group LLC now owns 9,766 shares of the biopharmaceutical company’s stock worth $691,000 after buying an additional 41 shares in the last quarter. 75.94% of the stock is owned by institutional investors.

In related news, EVP Gregg H. Alton sold 15,000 shares of Gilead Sciences stock in a transaction dated Wednesday, November 1st. The shares were sold at an average price of $74.82, for a total transaction of $1,122,300.00. Following the completion of the sale, the executive vice president now owns 77,363 shares in the company, valued at approximately $5,788,299.66. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, insider John F. Milligan sold 220,000 shares of Gilead Sciences stock in a transaction dated Monday, November 13th. The shares were sold at an average price of $72.88, for a total transaction of $16,033,600.00. The disclosure for this sale can be found here. Insiders have sold a total of 461,666 shares of company stock valued at $34,072,567 in the last quarter. 1.30% of the stock is currently owned by company insiders.

Shares of Gilead Sciences, Inc. (NASDAQ GILD) opened at $74.40 on Tuesday. Gilead Sciences, Inc. has a twelve month low of $63.76 and a twelve month high of $86.27. The firm has a market cap of $97,160.00, a PE ratio of 8.46, a P/E/G ratio of -1.58 and a beta of 1.13. The company has a current ratio of 3.68, a quick ratio of 3.56 and a debt-to-equity ratio of 1.10.

Gilead Sciences (NASDAQ:GILD) last announced its quarterly earnings data on Thursday, October 26th. The biopharmaceutical company reported $2.27 earnings per share for the quarter, beating analysts’ consensus estimates of $2.13 by $0.14. Gilead Sciences had a net margin of 42.22% and a return on equity of 57.15%. The company had revenue of $6.51 billion during the quarter, compared to analyst estimates of $6.40 billion. During the same quarter last year, the business posted $2.75 EPS. The firm’s revenue for the quarter was down 13.2% on a year-over-year basis. equities analysts forecast that Gilead Sciences, Inc. will post 8.53 earnings per share for the current fiscal year.

The business also recently disclosed a quarterly dividend, which was paid on Thursday, December 28th. Investors of record on Friday, December 15th were issued a dividend of $0.52 per share. The ex-dividend date was Thursday, December 14th. This represents a $2.08 dividend on an annualized basis and a yield of 2.80%. Gilead Sciences’s payout ratio is 23.66%.

A number of equities analysts have commented on the stock. BMO Capital Markets reissued a “hold” rating on shares of Gilead Sciences in a research note on Wednesday, January 3rd. Credit Suisse Group set a $80.00 price objective on shares of Gilead Sciences and gave the stock a “hold” rating in a research note on Wednesday, January 3rd. Mizuho reissued a “buy” rating on shares of Gilead Sciences in a research note on Friday, September 29th. Maxim Group reissued a “hold” rating on shares of Gilead Sciences in a research note on Thursday, October 19th. Finally, Oppenheimer reissued a “hold” rating on shares of Gilead Sciences in a research note on Thursday, December 21st. One analyst has rated the stock with a sell rating, fourteen have assigned a hold rating, sixteen have given a buy rating and one has assigned a strong buy rating to the stock. The stock has a consensus rating of “Buy” and a consensus target price of $85.03.

COPYRIGHT VIOLATION WARNING: “Gilead Sciences, Inc. (GILD) Shares Bought by Swiss National Bank” was originally reported by Community Financial News and is owned by of Community Financial News. If you are reading this report on another domain, it was stolen and republished in violation of U.S. and international copyright & trademark law. The original version of this report can be accessed at https://www.com-unik.info/2018/01/09/gilead-sciences-inc-gild-shares-bought-by-swiss-national-bank.html.

Gilead Sciences Profile

Gilead Sciences, Inc is a research-based biopharmaceutical company that discovers, develops and commercializes medicines in areas of unmet medical need. The Company’s portfolio of products and pipeline of investigational drugs includes treatments for Human Immunodeficiency Virus/Acquired Immune Deficiency Syndrome (HIV/AIDS), liver diseases, cancer, inflammatory and respiratory diseases and cardiovascular conditions.

Want to see what other hedge funds are holding GILD? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Gilead Sciences, Inc. (NASDAQ:GILD).

Institutional Ownership by Quarter for Gilead Sciences (NASDAQ:GILD)

What are top analysts saying about Gilead Sciences? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for Gilead Sciences and related companies.

Comments

Leave a Reply


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on Google Plus
share on reddit